| Literature DB >> 25698205 |
Ying Wu, Chao Long, Zhi-Guang Duan1.
Abstract
Entities:
Mesh:
Year: 2015 PMID: 25698205 PMCID: PMC4834784 DOI: 10.4103/0366-6999.151678
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Co-authored papers on depression research
| Year | Total papers ( | Co-authored papers ( | Percentage of co-authorship |
|---|---|---|---|
| 2003 | 8483 | 6880 | 81.1 |
| 2004 | 9920 | 8779 | 88.5 |
| 2005 | 10,294 | 9203 | 89.4 |
| 2006 | 11,393 | 10,163 | 89.2 |
| 2007 | 12,336 | 11,065 | 89.7 |
| 2008 | 13,603 | 12,311 | 90.5 |
| 2009 | 14,190 | 12,913 | 91.0 |
| 2010 | 14,993 | 13,764 | 91.8 |
| 2011 | 15,692 | 14,531 | 92.6 |
| 2012 | 16,772 | 15,648 | 93.3 |
Figure 1The structure map of the collaboration network among authors on depression research.
Annual institutional changes on depression research
| Year | Frequency of institutions ( | Actual institutions ( | Number of papers ( |
|---|---|---|---|
| 2003 | 19,425 | 5155 | 8483 |
| 2004 | 23,494 | 5966 | 9920 |
| 2005 | 24,977 | 6325 | 10,294 |
| 2006 | 26,078 | 6287 | 11,393 |
| 2007 | 32,266 | 7938 | 12,336 |
| 2008 | 37,153 | 8972 | 13,603 |
| 2009 | 39,902 | 9100 | 14,190 |
| 2010 | 44,172 | 10,314 | 14,993 |
| 2011 | 50,387 | 11,008 | 15,692 |
| 2012 | 53,391 | 11,881 | 16,772 |
Figure 2The structure map of the institutional collaboration network on depression research.
Figure 3Distribution of papers about countries’ collaboration.
Figure 4National distributions of papers.
Figure 5The structure map of the collaboration network among countries on depression research.
The relation between International collaboration and scientific papers
| Country | Collaboration | Production | ||
|---|---|---|---|---|
| Ranks | Ties | Papers | Ranks | |
| USA | 1 | 97 | 46,668 | 1 |
| England | 2 | 93 | 10,785 | 2 |
| Germany | 3 | 92 | 10,143 | 3 |
| France | 4 | 83 | 4814 | 9 |
| Australia | 5 | 82 | 6434 | 5 |
| Canada | 6 | 80 | 7914 | 4 |
| Italy | 7 | 80 | 5608 | 6 |
| Spain | 8 | 77 | 3625 | 11 |
| Switzerland | 9 | 76 | 2436 | 14 |
| Netherlands | 10 | 76 | 5358 | 7 |
| Japan | 11 | 72 | 4958 | 8 |
| India | 12 | 71 | 1488 | 16 |
| Belgium | 13 | 70 | 1644 | 15 |
| China | 14 | 69 | 4586 | 10 |
| Austria | 15 | 69 | 1251 | 18 |
| South Africa | 16 | 69 | 587 | 20 |
| Sweden | 17 | 67 | 2918 | 13 |
| Scotland | 18 | 67 | 1420 | 17 |
| Brazil | 19 | 66 | 3006 | 12 |
| Ireland | 20 | 61 | 1013 | 19 |
Figure 6Research focus on depression research. Cluster top terms in each sub-network: #0: Cancer pain inventory; #1: Symptom cluster; #2: Meta-analysis; #3: Omega-3; #4: Subgroup; #5: Inbreeding depression; #6: Downstream regulatory element antagonist modulator; #7: Cortical spreading depression; #8: Antidepressant treatment trial; #9: Ecstasy; #10: Familial risk factor; #11: Cytokine; #12: Arab emirate; #13: Pain; #14: Sleep quality; #15: Medication; #16: Future research; #17: Neurotics; #18: Serum level; #19: Ketamine; #20: Treatment-seeking behavior; #21: Neuropeptide; #22: Negative emotion; #23: Presynaptic serotonin function; #24: Major depression prevalence; #25: Individual patient data; #26: Controlled trial finding.
Information of clustering sub-network (2003-2012)
| Sub-network | Number of documents | Reprehensive documents | Cluster top term | Research focus |
|---|---|---|---|---|
| 0 | 2 | The pain catastrophizing scale: development and validation | Cancer pain inventory | Diagnosis and assessment |
| 1 | 1 | Olor vision deficits in Alzheimer’s disease | Symptom cluster | Behavioral biology |
| 2 | 2 | The Cochrane collaboration’s tool for assessing risk of bias in randomized trials | Meta-analysis | Diagnosis and assessment |
| 3 | 8 | Detection of postnatal depression-development of the 10-item Edinburgh postnatal depression scale | Omega-3 | Diagnosis and assessment |
| 4 | 73 | Statement on memories of sexual abuse | Subgroup | Behavioral biology |
| 5 | 9 | Inbreeding depression and its evolutionary consequences | Inbreeding depression | Behavioral biology |
| 6 | 12 | A synaptic model of memory-long-term potentiation in the hippocampus | Downstream regulatory element antagonist modulator | Neurotransmission |
| 7 | 2 | Mechanisms of migraine aura revealed by functional MRI in human visual cortex | Cortical spreading depression | Brain morphology |
| 8 | 11 | A rating scale for depression | Antidepressant treatment trial | Diagnosis and assessment |
| 9 | 8 | An inventory for measuring depression | Ecstasy | Diagnosis and assessment |
| 10 | 4 | Parkinsonismonset progression and mortality | Familial risk factor | Neurotransmission |
| 11 | 12 | Mini-mental state-practical method for grading the cognitive state of patients for clinician | Cytokine | Cognitive disorder |
| 12 | 14 | Validation and utility of a self-report version of PRIME-MD-The PHQ primary care study | Arab emirate | Diagnosis and assessment |
| 13 | 22 | The PHQ-9-validity of a brief depression severity measure | Pain | Diagnosis and assessment |
| 14 | 16 | The hospital anxiety and depression scale | Sleep quality | Diagnosis and assessment |
| 15 | 15 | The center for epidemiologic studies depression scale a self-report depression scale for research in the general population | Medication | Diagnosis and assessment |
| 16 | 13 | Comparison of beck depression inventories IA and-II in psychiatric outpatients | Future research | Diagnosis and assessment |
| 17 | 5 | Deep brain stimulation for treatment-resistant depression | Neuroethic | Neurotransmission |
| 18 | 37 | Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants | Serum level | Neurotransmission |
| 19 | 15 | Evaluation of outcomes with citapram for depression using measurement-based care in STAR*D: Implications for clinical practice | Ketamine | Diagnosis and assessment |
| 20 | 7 | Lifetime and 12-month prevalence of DSM-III-R psychiatric-disorders in the united – states-results from the national comorbidity-survey | Treatment-seeking behavior | Diagnosis and assessment |
| 21 | 21 | Deoressionnew animal-model sensitive to antidepressant treatments | Neuropeptide | Treatment |
| 22 | 9 | Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region | Negative emotion | Molecular genetics |
| 23 | 12 | Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene | Presynaptic serotonin function | Molecular genetics |
| 24 | 9 | Practice guideline for the treatment of patients with major depressive disorder (revision) | Major depression prevalence | Treatment |
| 25 | 5 | The MINI: The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 | Individual patient data | Diagnosis and assessment |
| 26 | 17 | The Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II).2.multisite test-retest reliability study | Controlled trial finding | Diagnosis and assessment |
MRI: Magnetic resonance imaging; PHQ: Patient Health Questionnaire; DSM: Diagnostic and Statistical Manual of Mental Disorders; MINI: Mini- International neuropsychiatric interview; ICD: International Classification of Diseases; SCID-II: Structured Clinical Interview for DSM-R Personality Disorders.